within Pharmacolibrary.Drugs.ATC.A;

model A10BK06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.051666666666666666,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.0636,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.03783333333333334,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor that reduces glucose reabsorption in the kidney and glucose absorption in the gut. It is used for the treatment of diabetes mellitus (mainly type 1, but also evaluated in type 2), although regulatory approval has been more limited than for selective SGLT2 inhibitors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral 400 mg dose.</p><h4>References</h4><ol><li><p>Powell, DR, et al., &amp; Lapuerta, P (2020). Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption. <i>The Journal of clinical endocrinology and metabolism</i> 105(4) e1235–e1249. DOI:<a href=&quot;https://doi.org/10.1210/clinem/dgz258&quot;>10.1210/clinem/dgz258</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31837264/&quot;>https://pubmed.ncbi.nlm.nih.gov/31837264</a></p></li><li><p>Tsimihodimos, V, et al., &amp; Elisaf, M (2018). SGLT1 inhibition: Pros and cons. <i>European journal of pharmacology</i> 838 153–156. DOI:<a href=&quot;https://doi.org/10.1016/j.ejphar.2018.09.019&quot;>10.1016/j.ejphar.2018.09.019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30240793/&quot;>https://pubmed.ncbi.nlm.nih.gov/30240793</a></p></li><li><p>Zambrowicz, B, et al., &amp; Powell, DR (2012). LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. <i>Clinical pharmacology and therapeutics</i> 92(2) 158–169. DOI:<a href=&quot;https://doi.org/10.1038/clpt.2012.58&quot;>10.1038/clpt.2012.58</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22739142/&quot;>https://pubmed.ncbi.nlm.nih.gov/22739142</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BK06;
